Royal Bank Of Canada Gt Biopharma, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.22 - $0.28 $52 - $66	-239 Reduced 9.81%	2,197 $0
Q3 2023 Nov 14, 2023	SELL	$0.24 - $0.35 $331 - $484	-1,383 Reduced 36.21%	2,436 $0
Q2 2023 Aug 14, 2023	BUY	$0.22 - $0.55 $288 - $721	1,311 Added 52.27%	3,819 $1,000
Q1 2023 May 15, 2023	SELL	$0.46 - $1.05 $128,547 - $293,422	-279,450 Reduced 99.11%	2,508 $1,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $58.2 $249,102 - $16.3 Million	279,890 Added 13534.33%	281,958 $250,000
Q3 2022 Nov 14, 2022	BUY	$1.81 - $56.1 $199 - $6,171	110 Added 5.62%	2,068 $3,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.11 $1,789 - $3,393	-1,091 Reduced 35.78%	1,958 $6,000
Q1 2022 May 16, 2022	SELL	$2.6 - $3.3 $8,652 - $10,982	-3,328 Reduced 52.19%	3,049 $9,000
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $6,841 - $15,880	2,243 Added 54.26%	6,377 $20,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $3,633 - $8,301	544 Added 15.15%	4,134 $28,000
Q2 2021 Aug 16, 2021	BUY	$7.19 - $18.96 $25,812 - $68,066	3,590 New	3,590 $55,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.